PATENT CLAIM ANALYSIS

Application Number: 16244368
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "263210"]

Abstract:
The present invention relates to novel quinazolinone derivatives inhibiting PI3K; a method for preparing the derivatives; and a pharmaceutical composition for treating hematologic neoplasms or liver diseases, containing the quinazolinone derivatives, wherein the novel quinazolinone derivatives according to the present invention have a beneficial effect in the treatment of hematologic neoplasms or liver diseases. Particularly, the quinazolinone derivatives inhibit PI3Kδ with high selectivity compared to that of a conventional anticancer drug of PI3Kδ inhibitors, thereby significantly reducing immunotoxicity, or simultaneously inhibit PI3Kδ and PI3Kγ, thereby enabling the treatment of autoimmune diseases, and anticancer therapy for blood cancer and the like. These targeted drugs have an advantage of enabling the problem of side effects of a conventional highly toxic anticancer therapy to be resolved.

Claim (Index 14):
The method of  claim 13 , wherein the hematological malignancy is selected from leukemia and lymphoma.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 99.0
- Lexical Diversity: 1.875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14488294', '14658189', '12971863', '14488296', '13762238']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.649832924089871
- 35 USC 102 Novelty (BERT): 0.509735511982894
- Combined Prediction Score: 0.6358231828791734
- Mean Citation Score: 235.32868
- Max Citation Score: 244.16003
- Similarity Product: 175.3129106780064

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test